Novartis and Health - An analysis by Rajeev DhavanApril 11 2013
The Novartis judgment has started a huge war of words. The patent drug producers are livid. They declare: “Woe is us. This is the end of invention.” The generic drug makers say: “Well done Supreme Court. Now we can supply life saving drugs to India and the world at cheaper prices.”
First let us understand the judgment for what it is. The drug in question is Gleevec which is used by cancer patients. The foundation for it is Imatinib Mesylate (IM) free base which was an important discovery and undoubtedly a new invention attributed to . . .
You need to have an active subscription to view this content.
With a premium account you get:
- One year of unrestrcited access to previous interviews, columns and articles
- One year access to all archival material
- Access to all Bar & Bench reports